Crescent Biopharma, Inc.
CBIO
$12.94
-$0.16-1.22%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Net Income | -21.79M | ||||
| Total Depreciation and Amortization | 2.00K | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 7.55M | ||||
| Change in Net Operating Assets | -2.16M | ||||
| Cash from Operations | -16.40M | ||||
| Capital Expenditure | -140.00K | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -140.00K | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | 144.28M | ||||
| Repurchase of Common Stock | -177.00K | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 2.76M | ||||
| Cash from Financing | 146.86M | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 130.32M | ||||